Danaher beats Q3 EPS estimates and raises full-year guidance, but shares fall premarket as 'beats aren't enough' theme spreads
What happened
Danaher Corporation reported third-quarter 2026 results on October 21: revenue rose 8.5% year over year to $6.55 billion (in line with estimates), and non-GAAP adjusted diluted EPS came in at $2.11, up 11.5% and well above the $1.91 average Wall Street estimate (a 9.9% beat per Zacks). The company raised its full-year 2026 adjusted diluted EPS guidance to $8.57-$8.62 from $8.45-$8.60, and said it expects 4%-5% core revenue growth (ex-respiratory) in the fourth quarter. Diagnostics sales jumped 17% on the Masimo acquisition, Biotechnology adjusted operating margin expanded 460 bps to 41.8%, and operating cash flow rose to $1.9 billion. Despite the beat and raise, Danaher shares traded lower before the open.
Why it matters & what’s next are part of Pro, along with the audio summary.
Start your free 14-day trialWho’s affected & sources
Who’s affected
- Danaher (DHR) — beat but shares lower premarket on the earnings-day rotation into defensive/managed-care names; read-through for the life-sciences tools group (Thermo Fisher, Agilent, Illumina) and the broader healthcare sector, which is seeing value-style outperformance this week.